Lack of cytoplasmic expression of a new marker programmed cell death ligand-1 in tumor cells is significant

doi:10.5493/wjem.v15.i4.110890

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 4

This Article

(44)

(48)

(0)

(18)

(816)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Exp Med. Dec 20, 2025; 15(4): 110890
Published online Dec 20, 2025. doi: 10.5493/wjem.v15.i4.110890

Full Size Figure Download Figure

Figure 2 Assessment of tumor-infiltrating programmed cell death protein 1 Ligand 1-positive immune cells. A: Cytoplasmic programmed cell death protein 1 ligand 1 (cPDCD1 LG1) + immune cell score ≥ 30%; B: PDCD1 LG1+ immune cell score < 10%. Staining with anti-PDCD1 LG1 antibodies. The scale bar is 200 μm.

Citation: Senchukova MA, Zubareva EY, Saidler NV, Krivolapova LV. Lack of cytoplasmic expression of a new marker programmed cell death ligand-1 in tumor cells is significant. World J Exp Med 2025; 15(4): 110890
URL: https://www.wjgnet.com/2220-315x/full/v15/i4/110890.htm
DOI: https://dx.doi.org/10.5493/wjem.v15.i4.110890

Senchukova MA, Zubareva EY, Saidler NV, Krivolapova LV. Lack of cytoplasmic expression of a new marker programmed cell death ligand-1 in tumor cells is significant. World J Exp Med 2025; 15(4): 110890 [PMID: 41497695 DOI: 10.5493/wjem.v15.i4.110890]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.